Strategic responses to parallel trade

B.E. Journal of Economic Analysis and Policy

Volumn 11, Issue 2, 2011, Pages

  Kyle, Margaret ^a  

^a TOULOUSE SCHOOL OF ECONOMICS   (France)

Author keywords

competition policy; intellectual property; parallel trade; pharmaceuticals

Indexed keywords

EID: 79951534968     PISSN: None     EISSN: 19351682     Source Type: Journal    
DOI: 10.2202/1935-1682.2629     Document Type: Article

References (34)

1. Arfwedson, J. (2004), "Re-importation (Parallel Trade) in Pharmaceuticals," Institute for Policy Innovation Policy Report 192.
2. Anderson, S. and V. Ginsburgh (1999), "International Pricing with Costly Arbitrage," Review of International Economics 7(1), 126-139.
3. Committee on Government Reform Special Investigations Division (2002), "Prescription Drugs Are More Expensive in Rep. Waxman's Congressional District in California than in Canada, Europe, and Japan."
4. Dafny, L. (2005a), "How Do Hospitals Respond to Price Changes?" (Pubitemid 43550742)
5. Dafny, L. (2005b), "Games Hospitals Play: Entry Deterrence in Hospital Procedure Markets," Journal of Economics and Management Strategy 14(3): 513-542. (Pubitemid 41239668)
6. Danzon, P. and A. Epstein (2005), "Launch and Pricing Strategies of Pharmaceuticals in Interdependent Markets," University of Pennsylvania working paper.
7. Danzon, P. and M. Furukawa (2003), "Prices and Availability of Pharmaceuticals: Evidence From Nine Countries," Health Affairs Web Exclusive. October 2003.
8. Danzon, P., R. Wang and L. Wang (2005), "The Impact of Price Regulation on the Launch Delay of New Drugs," Health Economics, 14(3).
9. Danzon, P. and L. Chao (2000), "Cross-National Price Differences for Pharmaceuticals: How Large and Why?" Journal of Health Economics 19:159-195. (Pubitemid 30177260)
10. Danzon, P. (1998), "The Economics of Parallel Trade," PharmacoEconomics 13(3):293-304. (Pubitemid 28123369)
11. Duggan, M. and F. Scott Morton (2006), "The Distortionary Effects of Government Procurement: Evidence from Medicaid Prescription Drug Purchasing," Quarterly Journal of Economics 121(1), 1-30. (Pubitemid 43374414)
12. Ellison, G. and S. Ellison (2007), "Strategic Entry Deterrence and the Behavior of Pharmaceutical Incumbents Prior to Patent Expiration," MIT Working Paper.
13. Ganslandt, M. and K. Maskus (2004), "The Price Impact of Parallel Imports in Pharmaceuticals: Evidence from the European Union," Journal of Health Economics 23(5), 1035-1057. (Pubitemid 39194976)
14. Goldberg, P. and F. Verboven (2005), "Market Integration and Convergence to the Law of One Price: Evidence from the European Car Market," Journal of International Economics 65(1), 45-73.
15. Goolsbee, A. and C. Syverson (2008), "How Do Incumbents Respond to the Threat of Entry? Evidence from the Major Airlines," Quarterly Journal of Economics 123(4), 1611-1633.
16. Grossman, G. and E. Lai (2008), "Parallel Imports and Price Controls," RAND Journal of Economics, forthcoming.
17. Kanavos, P., J. Costa-i-Font, S. Merkur, and M. Gemmill (2004), "The Economic Impact of Pharmaceutical Parallel Trade in European Union Member States: A Stakeholder Analysis," LSE Health and Social Care Special Research Paper.
18. Kyle, M. (2007), "Pharmaceutical Price Controls and Entry Strategies," Review of Economics and Statistics 89(1), 88-99.
19. Kyle, M. (2009), "Parallel Trade in Pharmaceuticals: Firm Responses and Competition Policy," Chapter 13 in B. Hawk (ed.), International Antitrust Law & Policy: Fordham Competition Law 2009, Juris Publishing, New York.
20. Kyle, M., J. Allsbrook and K. Schulman (2008), "Does Reimportation Reduce Price Differences for Prescription Drugs? Lessons from the European Union," Health Services Research 43(4), 1308-1324. (Pubitemid 352019152)
21. Lanjouw, J. (2005), "Price controls, patents, and the availability of drugs," NBER working paper.
22. Malueg, D. and M. Schwartz (1994), "Parallel imports, demand dispersion, and international price discrimination," Journal of International Economics 37(3-4), 167-195.
23. Mazzeo, M. (2002), "Product Choice and Oligopoly Market Structure," RAND Journal of Economics 33(2), p. 221-242.
24. Medicins Sans Frontiers (2001), "Recommendations to the European Commission for discussions at the June 2001 TRIPS Council on Health and Access to Medicines," msf.org website.
25. Qian, Y. (2008), "Impact of Entry by Counterfeiters," Quarterly Journal of Economics 123(4), 1577-1609.
26. Rey, P. (2003), "The Impact of Parallel Imports on Prescription Medicines," University of Toulouse working paper.
27. Scott Morton, F. (1997a), "The Strategic Response by Pharmaceutical Firms to the Medicaid Most-Favored-Customer Rules." RAND Journal of Economics 28:2, 269-290.
28. Scott Morton, F. (1997b), "The Interaction Between a MFC Clause and Price Dispersion: An Empirical Examination of the Medicaid Rebate Rules of 1990," Journal of Economics and Management Strategy 6(1),151-174.
29. Stuart, B., N. Brandt, N. Briesacher, C. Fahlman, D. Mullons, F. Palumbo, J. Pizarro, and L. Stuart (2000), "Issues in Prescription Drug Coverage, Pricing, Utilization and Spending: What We Know and Need to Know," United States Department of Health and Human Services Office of Health Policy Report.
30. Szymanski, S. and T. Valletti (2005), "Parallel trade, price discrimination, investment and price caps," Economic Policy 20, 705-749. (Pubitemid 44308874)
31. Szymanski, S. and T. Valletti (2006), "Parallel Trade, International Exhaustion and Intellectual Property Rights: A Welfare Analysis," Journal of Industrial Economics 54(4), 499-526. (Pubitemid 44967720)
32. Taylor, D., M. Mrazek and E. Mossialos (2004), "Regulating pharmaceutical distribution and retail pharmacy in Europe," Chapter 11 in Mossialos, E. M. Mrazek and T. Walley (eds.), Regulating Pharmaceuticals in Europe, Open University Press, Berkshire, England.
33. Urch Publishing (2001), The Guide to European Pharmaceutical Pricing and Reimbursement Systems, London, United Kingdom.
34. Varian, H. (1985), "Price Discrimination and Social Welfare," American Economic Review 75:870-875.